Literature DB >> 32719042

Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging.

Christian Schmidkonz1, Simon Rauber2, Armin Atzinger1, Rahul Agarwal2, Theresa Ida Götz1, Alina Soare2, Michael Cordes1, Olaf Prante1, Christina Bergmann2, Arnd Kleyer2, Philipp Ritt1, Simone Maschauer1, Peter Hennig1, Johannes Toms1, Markus Köhner1, Bernhard Manger2, John H Stone3, Uwe Haberkorn4, Tobias Baeuerle5, Jörg H W Distler2, Abbas Agaimy6, Torsten Kuwert1, Georg Schett2, Andreas Ramming7.   

Abstract

OBJECTIVES: To date, there is no valuable tool to assess fibrotic disease activity in humans in vivo in a non-invasive way. This study aims to uncouple inflammatory from fibrotic disease activity in fibroinflammatory diseases such as IgG4-related disease.
METHODS: In this cross-sectional clinical study, 27 patients with inflammatory, fibrotic and overlapping manifestations of IgG4-related disease underwent positron emission tomography (PET) scanning with tracers specific for fibroblast activation protein (FAP; 68Ga-FAP inhibitor (FAPI)-04), 18F-fluorodeoxyglucose (FDG), MRI and histopathological assessment. In a longitudinal approach, 18F-FDG and 68Ga-FAPI-04 PET/CT data were evaluated before and after immunosuppressive treatment and correlated to clinical and MRI data.
RESULTS: Using combination of 68Ga-FAPI-04 and 18F-FDG-PET, we demonstrate that non-invasive functional tracking of IgG4-related disease evolution from inflammatory towards a fibrotic outcome becomes feasible. 18F-FDG-PET positive lesions showed dense lymphoplasmacytic infiltration of IgG4 + cells in histology, while 68Ga-FAPI-04 PET positive lesions showed abundant activated fibroblasts expressing FAP according to results from RNA-sequencing of activated fibroblasts. The responsiveness of fibrotic lesions to anti-inflammatory treatment was far less pronounced than that of inflammatory lesions.
CONCLUSION: FAP-specific PET/CT permits the discrimination between inflammatory and fibrotic activity in IgG4-related disease. This finding may profoundly change the management of certain forms of immune-mediated disease, such as IgG4-related disease, as subtypes dominated by fibrosis may require different approaches to control disease progression, for example, specific antifibrotic agents rather than broad spectrum anti-inflammatory treatments such as glucocorticoids. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  fibroblasts; inflammation; outcome assessment, health care

Year:  2020        PMID: 32719042     DOI: 10.1136/annrheumdis-2020-217408

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  27 in total

1.  Non-invasive imaging reveals fibrotic activity in IgG4-RD.

Authors:  Sarah Onuora
Journal:  Nat Rev Rheumatol       Date:  2020-10       Impact factor: 20.543

2.  Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis.

Authors:  Yue Zhou; Xin Yang; Huipan Liu; Wenbin Luo; Hanxiang Liu; Taiyong Lv; Junzheng Wang; Jianhua Qin; Santao Ou; Yue Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-07       Impact factor: 9.236

3.  Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.

Authors:  Liang Zhao; Yizhen Pang; Hua Zheng; Chengkun Han; Jianwei Gu; Long Sun; Hua Wu; Sangang Wu; Qin Lin; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-01       Impact factor: 9.236

4.  Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer.

Authors:  Yizhen Pang; Long Zhao; Qihang Shang; Tinghua Meng; Liang Zhao; Liuxing Feng; Shuangjia Wang; Ping Guo; Xiurong Wu; Qin Lin; Hua Wu; Weipeng Huang; Long Sun; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

5.  The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.

Authors:  Lianjun Lan; Hanxiang Liu; Yingwei Wang; Jia Deng; Dengsai Peng; Yue Feng; Li Wang; Yue Chen; Lin Qiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-19       Impact factor: 9.236

Review 6.  [Immunoglobulin-G4-related disease].

Authors:  Jasper F Nies; Martin Krusche
Journal:  Z Rheumatol       Date:  2022-06-29       Impact factor: 1.530

7.  State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.

Authors:  Martina Sollini; Margarita Kirienko; Fabrizia Gelardi; Francesco Fiz; Noemi Gozzi; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-25       Impact factor: 9.236

8.  Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas.

Authors:  Xiao Zhang; Wenyu Song; Chunxia Qin; Fang Liu; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-15       Impact factor: 9.236

9.  68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial.

Authors:  Lukas Kessler; Justin Ferdinandus; Nader Hirmas; Sebastian Bauer; Uta Dirksen; Fadi Zarrad; Michael Nader; Michal Chodyla; Aleksandar Milosevic; Lale Umutlu; Martin Schuler; Lars Erik Podleska; Hans-Ulrich Schildhaus; Wolfgang P Fendler; Rainer Hamacher
Journal:  J Nucl Med       Date:  2021-04-30       Impact factor: 11.082

10.  Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond.

Authors:  Chunxia Qin; Yangmeihui Song; Xi Liu; Yongkang Gai; Qingyao Liu; Weiwei Ruan; Fang Liu; Fan Hu; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-09       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.